• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogues.

作者信息

Hicks Rodney J, Kwekkeboom Dik J, Krenning Eric, Bodei Lisa, Grozinsky-Glasberg Simona, Arnold Rudolf, Borbath Ivan, Cwikla Jaroslaw, Toumpanakis Christos, Kaltsas Greg, Davies Philippa, Hörsch Dieter, Tiensuu Janson Eva, Ramage John

机构信息

Cancer Imaging and Neuroendocrine Service, the Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

出版信息

Neuroendocrinology. 2017;105(3):295-309. doi: 10.1159/000475526. Epub 2017 Apr 13.

DOI:10.1159/000475526
PMID:28402980
Abstract
摘要

相似文献

1
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogues.ENETS神经内分泌肿瘤护理标准共识指南：放射性标记生长抑素类似物的肽受体放射性核素治疗
Neuroendocrinology. 2017;105(3):295-309. doi: 10.1159/000475526. Epub 2017 Apr 13.
2
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs.神经内分泌肿瘤护理标准的ENETS共识指南：放射性标记生长抑素类似物的肽受体放射性核素治疗
Neuroendocrinology. 2009;90(2):220-6. doi: 10.1159/000225951. Epub 2009 Aug 28.
3
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide.神经内分泌肿瘤治疗标准的欧洲神经内分泌肿瘤学会（ENETS）共识指南：使用（111）铟-奥曲肽进行生长抑素受体显像
Neuroendocrinology. 2009;90(2):184-9. doi: 10.1159/000225946. Epub 2009 Aug 28.
4
Tumor imaging and therapy using radiolabeled somatostatin analogues.使用放射性标记的生长抑素类似物进行肿瘤成像和治疗。
Acc Chem Res. 2009 Jul 21;42(7):873-80. doi: 10.1021/ar800188e.
5
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biotherapy.神经内分泌肿瘤治疗标准的ENETS共识指南：生物疗法
Neuroendocrinology. 2009;90(2):209-13. doi: 10.1159/000183751. Epub 2009 Aug 28.
6
Peptide Receptor Radionuclide Therapy (PRRT) of Medullary and Nonmedullary Thyroid Cancer Using Radiolabeled Somatostatin Analogues.使用放射性标记的生长抑素类似物对髓样和非髓样甲状腺癌进行肽受体放射性核素治疗（PRRT）。
Semin Nucl Med. 2016 May;46(3):215-24. doi: 10.1053/j.semnuclmed.2016.01.010.
7
Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors.生长抑素类似物在神经内分泌肿瘤治疗中的作用
Hematol Oncol Clin North Am. 2016 Feb;30(1):163-77. doi: 10.1016/j.hoc.2015.09.008.
8
Patient selection for personalized peptide receptor radionuclide therapy using Ga-68 somatostatin receptor PET/CT.使用Ga-68生长抑素受体PET/CT进行个性化肽受体放射性核素治疗的患者选择。
PET Clin. 2014 Jan;9(1):83-90. doi: 10.1016/j.cpet.2013.08.015.
9
Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours.在生长抑素受体阳性肿瘤患者中使用放射性标记的生长抑素类似物进行肽受体放射性核素治疗。
Acta Oncol. 2007;46(6):723-34. doi: 10.1080/02841860701441848.
10
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors.神经内分泌肿瘤护理标准的ENETS共识指南：神经内分泌肿瘤患者的术前和围手术期治疗
Neuroendocrinology. 2017;105(3):245-254. doi: 10.1159/000461583. Epub 2017 Mar 2.

引用本文的文献

1
Effect of previous Lu-DOTATATE treatment on Y-microsphere treatment response in neuroendocrine tumor patients with liver metastasis.既往使用镥-奥曲肽治疗对肝转移神经内分泌肿瘤患者钇微球治疗反应的影响。
Ann Nucl Med. 2025 Aug 25. doi: 10.1007/s12149-025-02101-z.
2
Predictors of renal function decline in patients with gastroenteropancreatic neuroendocrine tumors undergoing [177Lu]Lu-DOTA-TATE therapy.接受[177Lu]Lu-DOTA-TATE治疗的胃肠胰神经内分泌肿瘤患者肾功能下降的预测因素。
EJNMMI Res. 2025 Aug 21;15(1):110. doi: 10.1186/s13550-025-01305-8.
3
First-in-human experience of radiopharmaceutical therapy with [Lu]Lu-DOTATATE in patients with advanced multiple myeloma.
[镥]镥-奥曲肽放射性药物治疗晚期多发性骨髓瘤患者的首例人体试验经验。
EJNMMI Rep. 2025 Jul 28;9(1):26. doi: 10.1186/s41824-025-00262-8.
4
Neuroendocrine Neoplasms in Pregnancy: A Narrative Review of Clinical Challenges and Therapeutic Limitations in the Absence of Established Safe Treatments.妊娠期神经内分泌肿瘤：在缺乏既定安全治疗方法情况下临床挑战与治疗局限性的叙述性综述
J Pers Med. 2025 Jun 25;15(7):272. doi: 10.3390/jpm15070272.
5
The PANEN nomogram: clinical decision support for patients with metastatic pancreatic neuroendocrine neoplasm referred for peptide receptor radionuclide therapy.PANEN列线图：为接受肽受体放射性核素治疗的转移性胰腺神经内分泌肿瘤患者提供临床决策支持。
Front Endocrinol (Lausanne). 2025 Jun 24;16:1514792. doi: 10.3389/fendo.2025.1514792. eCollection 2025.
6
Case of the Season: Lu-DOTATATE Peptide Receptor Radiotherapy With Acute Dialysis Support in a Patient With Chronic Kidney Disease (CKD).本季病例：一名慢性肾脏病（CKD）患者接受镥-奥曲肽肽受体放射性核素治疗并获得急性透析支持
Semin Roentgenol. 2025 Jul;60(3):233-237. doi: 10.1053/j.ro.2025.03.001. Epub 2025 Apr 12.
7
Association of integrated biomarkers and progression-free survival prediction in patients with gastroenteropancreatic neuroendocrine tumors undergoing [177Lu]Lu-DOTA-TATE therapy.接受[177Lu]Lu-DOTA-TATE治疗的胃肠胰神经内分泌肿瘤患者中综合生物标志物与无进展生存预测的关联
Theranostics. 2025 May 25;15(13):6444-6453. doi: 10.7150/thno.112588. eCollection 2025.
8
Six-Year Outcomes Following Stereotactic Body Radiation Therapy for Insulinoma: A Case Report and Literature Review.立体定向体部放射治疗胰岛素瘤的六年疗效：病例报告及文献综述
Cureus. 2025 May 5;17(5):e83535. doi: 10.7759/cureus.83535. eCollection 2025 May.
9
Personal Health Record Software for Neuroendocrine Tumors: Patient-Centered Design Approach.神经内分泌肿瘤的个人健康记录软件：以患者为中心的设计方法。
JMIR Hum Factors. 2025 Jun 3;12:e68788. doi: 10.2196/68788.
10
Case Report: PRRT in a patient with Zollinger-Ellison syndrome. The management of gastrointestinal complications.病例报告：一名卓-艾综合征患者的肽受体放射性核素治疗。胃肠道并发症的处理
Front Oncol. 2025 May 19;15:1590478. doi: 10.3389/fonc.2025.1590478. eCollection 2025.